(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1547418

モノクローナル抗体の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Monoclonal Antibody Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
モノクローナル抗体の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

モノクローナル抗体市場の世界需要は、2023年の2,362億3,000万米ドルから2032年には約2,691億5,000万米ドルの市場規模に達すると推定され、調査期間2024～2032年のCAGRは1.46%です。

モノクローナル抗体（mAbまたはmoAb）は、実験室で作られるタンパク質で、体内の物質と結合することができます。単一のB細胞クローンから生成される同一の免疫グロブリンです。モノクローナル抗体は多くの疾患の治療に使用され、単独で使用することも、薬剤、毒素、放射性物質を運ぶこともできます。モノクローナル抗体には多くタイプがあり、作り方も様々で、キメラ、マウス、ヒト化、ヒトなど、作り方によって名前が付けられています。モノクローナル抗体は、単一の抗原上のユニークなエピトープ（結合部位）を認識します。モノクローナル抗体は、免疫系においてヒト抗体のように作用します。

市場力学

モノクローナル抗体（mAbまたはmoAb）は生化学、分子生物学、医療において重要なツールとなっています。慢性疾患やがんの罹患率の上昇、規制当局の承認の増加、治療の発売、研究開発の拡大が主に世界のモノクローナル抗体市場を牽引しています。慢性疾患とがんは世界の死因のトップです。世界保健機関（WHO）の推定によると、慢性疾患は世界全体の死因の約3分の2を占めています。2020年には、がんが約1,000万人の死因となっています。モノクローナル抗体は、COVID-19のパンデミックの台頭とともに注目されるようになりました。モノクローナル抗体は、より広く使用されるように進歩しています。モノクローナル抗体は製薬業界に多くの利点をもたらし、COVID-19パンデミックを治療することができます。モノクローナル抗体は、COVID-19患者を治療するための有望なアプローチとして同定されています。COVID-19を治療するためにこれを使用するための研究が活発に行われています。しかし、モノクローナル抗体に関連するコストの高さ、厳しい規制措置、モノクローナル抗体に関する認知度の低さ、調査不足が市場成長の妨げになる可能性が高いです。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、モノクローナル抗体の世界市場における各セグメントを包括的に評価することもできます。モノクローナル抗体産業の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

モノクローナル抗体市場レポートのこのセクションでは、国別と地域別のセグメントに関する詳細なデータを提供し、それによって戦略家がそれぞれの製品またはサービスの対象層を特定する上で、今後のビジネス機会を支援します。

地域別分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるモノクローナル抗体市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 モノクローナル抗体産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 モノクローナル抗体の世界市場分析：供給源別

  • 供給源別概要
  • 供給源別過去・予測データ分析
  • マウス
  • キメラ
  • ヒト化
  • ヒト

第6章 モノクローナル抗体の世界市場分析：生産別

  • 生産別概要
  • 生産別過去・予測データ分析
  • In vivo
  • In vitro

第7章 モノクローナル抗体の世界市場分析：用途別

  • 用途別概要
  • 用途別過去・予測データ分析
  • がん領域
  • 自己免疫疾患
  • 感染症
  • 神経疾患
  • その他

第8章 モノクローナル抗体の世界市場分析：最終用途別

  • 最終用途別概要
  • 最終用途別過去・予測データ分析
  • 病院
  • 専門センター
  • その他

第9章 モノクローナル抗体の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第10章 モノクローナル抗体企業の競合情勢

  • モノクローナル抗体市場の競合
  • 提携/共同研究/契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Novartis AG
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Merck & Co. Inc.
  • Daiichi Sankyo Company
  • Limited
  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly And Company
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Bristol Myers Squibb
  • F. Hoffman-La Roche Ltd.
  • Viatris Inc.
  • Biogen Inc.
  • Thermo Fisher Scientific Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Merck KGaA
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Monoclonal Antibody Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Monoclonal Antibody Report
  • Market Research Process
  • Market Research Methodology
  • Global Monoclonal Antibody Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Source
  • Market Attractiveness Analysis By Production
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Global Market Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11215463

The global demand for Monoclonal Antibody Market is presumed to reach the market size of nearly USD 269.15 Billion by 2032 from USD 236.23 Billion in 2023 with a CAGR of 1.46% under the study period 2024-2032.

Monoclonal antibodies (mAb or moAb) are a protein type made in the laboratory that can bind to substances in the body. They are identical immunoglobulins generated from a single B-cell clone. Monoclonal antibodies are employed to treat many diseases and can be used alone or carry drugs, toxins, or radioactive substances. There are many varieties of monoclonal antibodies and different ways of making them, and they are named based on how they are made of chimeric, murine, humanized, and human. Monoclonal antibodies recognize unique epitopes, or binding sites, on a single antigen. They act like human antibodies in the immune system.

MARKET DYNAMICS

Monoclonal antibodies (mAb or moAb) have become an important tool in biochemistry, molecular biology, and medicine. Rising incidence of chronic diseases and cancer, increasing regulatory approvals, the launch of therapies, and growing R&D primarily drive the global monoclonal antibody market. Chronic diseases and cancer are the leading cause of death worldwide. According to the World Health Organization estimates, chronic diseases are responsible for around two-thirds of all deaths worldwide. In 2020, cancer caused the death of nearly 10 million people. Monoclonal antibodies have gained attention with the rise of the COVID-19 pandemic. They have progressed to allow more widespread use. Monoclonal antibodies offer many benefits to the pharmaceutical industry and treat the COVID-19 pandemic, including short production time, low cost, highly stable and tolerant of pH or buffer changes, high affinity, and tolerance of minor antigen changes. Monoclonal antibodies are identified as a promising approach for treating COVID-19 patients. Robust research is being carried out to use it to treat COVID-19. However, higher costs associated with a monoclonal antibody, strict regulatory measures, low awareness about monoclonal antibody, and lack of research is likely to hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibody. The growth and trends of Monoclonal Antibody industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Monoclonal Antibody market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

  • Murine
  • Chimeric
  • Humanized
  • Human

By Production

  • In Vivo
  • In Vitro

By Application

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Others

By End-use

  • Hospitals
  • Specialty Centers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibody market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibody market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc., Bayer AG, Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Biogen Inc., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Sanofi S.A., Merck KGaA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. MONOCLONAL ANTIBODY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Source
    • 3.7.2 Market Attractiveness Analysis By Production
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY SOURCE

  • 5.1. Overview By Source
  • 5.2. Historical and Forecast Data Analysis By Source
  • 5.3. Murine Historic and Forecast Sales By Regions
  • 5.4. Chimeric Historic and Forecast Sales By Regions
  • 5.5. Humanized Historic and Forecast Sales By Regions
  • 5.6. Human Historic and Forecast Sales By Regions

6. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY PRODUCTION

  • 6.1. Overview By Production
  • 6.2. Historical and Forecast Data Analysis By Production
  • 6.3. In Vivo Historic and Forecast Sales By Regions
  • 6.4. In Vitro Historic and Forecast Sales By Regions

7. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data Analysis By Application
  • 7.3. Oncology Historic and Forecast Sales By Regions
  • 7.4. Autoimmune Diseases Historic and Forecast Sales By Regions
  • 7.5. Infectious Diseases Historic and Forecast Sales By Regions
  • 7.6. Neurological Diseases Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-use
  • 8.2. Historical and Forecast Data Analysis By End-use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Centers Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODY COMPANIES

  • 10.1. Monoclonal Antibody Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF MONOCLONAL ANTIBODY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Novartis AG
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. GlaxoSmithKline Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Amgen Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Merck & Co. Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Daiichi Sankyo Company
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Limited
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Abbott Laboratories
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. AstraZeneca Plc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Eli Lilly And Company
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Johnson & Johnson Services Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Bayer AG
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Bristol Myers Squibb
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. F. Hoffman-La Roche Ltd.
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. Viatris Inc.
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments
  • 11.18. Biogen Inc.
    • 11.18.1 Company Overview
    • 11.18.2 Company Revenue
    • 11.18.3 Products
    • 11.18.4 Recent Developments
  • 11.19. Thermo Fisher Scientific Inc.
    • 11.19.1 Company Overview
    • 11.19.2 Company Revenue
    • 11.19.3 Products
    • 11.19.4 Recent Developments
  • 11.20. Novo Nordisk A/S
    • 11.20.1 Company Overview
    • 11.20.2 Company Revenue
    • 11.20.3 Products
    • 11.20.4 Recent Developments
  • 11.21. Sanofi S.A.
    • 11.21.1 Company Overview
    • 11.21.2 Company Revenue
    • 11.21.3 Products
    • 11.21.4 Recent Developments
  • 11.22. Merck KGaA
    • 11.22.1 Company Overview
    • 11.22.2 Company Revenue
    • 11.22.3 Products
    • 11.22.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies